Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.
At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.
Corporate responsibility is at the core of our business strategy and culture. It runs through everything we do. We want to create a net positive impact for patients, employees, partners and wider society, and work towards reducing our impact on the environment.
Having access to appropriate pain treatment is a basic human right. As a leader in pain management, we help to educate healthcare professionals and patients on how to use these medicines responsibly. We also raise awareness and increase accessibility to current treatments while developing new medicines for unmet medical needs.
How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us.
We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.
Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.
Aachen, Germany, 16 December 2020 Grünenthal announced today that the first participants have
been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP)
agonist, an oral investigational medicine with a unique mechanism of action for the treatment of
chronic peripheral neuropathic pain.
Aachen, Germany, 1 December 2020 Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR™ (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. CRESTOR™ is among the leading statin products in Europe and is indicated for the treatment of dyslipidaemia, hypercholesterolaemia and the prevention of cardiovascular events. Compared to other statins such as atorvastatin, CRESTOR™ has demonstrated superior LDL- cholesterol- lowering efficacy1. The level of LDL is an important factor for the improvement of cardiovascular outcomes and therefore especially important in patients with high risk of cardiovascular diseases such as diabetes or stroke.
Aachen, Germany & Morristown, N.J. – 21 July 2020 – Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.2 QUTENZA® is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin.
Aachen, Deutschland, 16. Juni 2020 – Grünenthal, ein weltweit führendes Unternehmen im Bereich der Schmerzbehandlung und verwandten Erkrankungen, durfte sich am 15. Juni 2020 über eine besondere Auszeichnung freuen: Bereits zum vierten Mal wurde das Aachener Unternehmen mit dem renommierten Zertifikat zum audit berufundfamilie ausgezeichnet – diesmal jedoch sogar mit dem Zusatz „mit dauerhaftem Charakter“. Damit wird das Zertifikat, das als Qualitätssiegel für eine strategisch angelegte familien- und lebensphasenbewusste Personalpolitik gilt, nicht mehr nur für einen bestimmten Zeitraum, sondern dauerhaft vergeben. Zu den Gratulant*innen zählte unter anderem Bundesfamilienministerin Dr. Franziska Giffey, die die Schirmherrschaft übernommen hat.
Aachen, Germany, 04 February 2020 – Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of company cars for managers at its site in Aachen, Germany. The decision is part of the company’s ongoing commitment to promoting sustainability by reducing the environmental footprint of its operations. And it also marks the latest step forward in its long tradition of investing in future-facing technologies.
Aachen, Germany and Boston, USA / 29 January 2020 — Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with leading scientists and institutions.